UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012503
Receipt number R000014611
Scientific Title Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study
Date of disclosure of the study information 2013/12/25
Last modified on 2015/07/17 11:50:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study

Acronym

Creatine in SBMA

Scientific Title

Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study

Scientific Title:Acronym

Creatine in SBMA

Region

Japan


Condition

Condition

Spinal and Bulbar Muscular Atrophy

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of the creatine supplementation in SBMA patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Grip power

Key secondary outcomes

(1) Muscle strength measured by quantitative muscle testing
(2) Motor function: tongue pressure, Timed walk test, Rise from bed test, and modified QMG Score
(3) Respiratory function test: vital capacity, forced vital capacity, forced expiratory volume one second percent, peak expiratory flow and V50/V25
(4) Activities of daily living(ADL) assessed by ALSFRS-R and SBMAFRS questionnaires
(5) Swallowing Disturbance Questionnaire
(6) Quality of life questionnaires: SWAL-QOL and ALSAQ-5
(7) Multidimensional Fatigue Inventory
(8) Muscle mass measured by dual-energy X-ray absorptiometry
(9) urinary 8-OHdG


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Creatine monohydrate 10 g, daily for 8 weeks

Interventions/Control_2

Creatine monohydrate 15 g, daily for 8 weeks

Interventions/Control_3

placebo for 8 weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male

Key inclusion criteria

1. Patients (males) whose number of the CAG repeat in the androgen receptor gene is more than 38
2. Patients with muscle weakness
3. Patients are between 20 and 80 years old at the time of the agreement acquisition
4. Patients who are capable of ambulatory hospital visits
5. Patients whose renal functions meet the following criteria:
Serum creatinine: <1.5 * Upper Limit of Institutional Reference Value
6. Patients with written informed consent

Key exclusion criteria

1.Patients who have taken LH-RH agonists, an LH-RH antagonists, teststerone drugs, anti-androgen drugs, estrogen drugs or unapproved drug within 48 weeks before agreement acquisition and patients who have taken 5-alpha-reductase inhibitors within 24 weeks before agreement acquisition.
2. Patients whose serum testosterone level is below the lower limit of normal.
3. Patients who have taken creatine supplementation within 8 weeks before agreement acquisition
4. Patients who have severe complications
5. Patients who are not appropriate to participate in the trial

Target sample size

45


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Gen Sobue

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Neurology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan

TEL

052-744-2385

Email

sobueg@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yasuhiro Hijikata

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Neurology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan

TEL

052-744-2390

Homepage URL


Email

hijikata@med.nagoya-u.ac.jp


Sponsor or person

Institute

Department of Neurology, Nagoya University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

Center for Advanced Medicine and Clinical Research, Nagoya University Hospital


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋大学医学部附属病院(愛知県)


Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 12 Month 25 Day

Date of IRB


Anticipated trial start date

2014 Year 06 Month 01 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry

2016 Year 01 Month 31 Day

Date trial data considered complete

2016 Year 02 Month 28 Day

Date analysis concluded

2016 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 12 Month 05 Day

Last modified on

2015 Year 07 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014611


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name
2018/06/19 CRECKET-Results.xlsx